Quent Capital LLC Has $4.33 Million Stake in Eli Lilly and Company $LLY

Quent Capital LLC lowered its stake in shares of Eli Lilly and Company (NYSE:LLY) by 0.5% in the second quarter, according to its most recent disclosure with the SEC. The fund owned 5,549 shares of the company’s stock after selling 26 shares during the period. Quent Capital LLC’s holdings in Eli Lilly and Company were worth $4,325,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in the stock. Future Financial Wealth Managment LLC raised its position in shares of Eli Lilly and Company by 7.6% during the second quarter. Future Financial Wealth Managment LLC now owns 1,698 shares of the company’s stock valued at $1,324,000 after buying an additional 120 shares during the last quarter. Ameriflex Group Inc. raised its position in shares of Eli Lilly and Company by 4.7% during the second quarter. Ameriflex Group Inc. now owns 1,170 shares of the company’s stock valued at $930,000 after buying an additional 52 shares during the last quarter. QRG Capital Management Inc. raised its position in shares of Eli Lilly and Company by 2.5% during the second quarter. QRG Capital Management Inc. now owns 129,427 shares of the company’s stock valued at $100,892,000 after buying an additional 3,202 shares during the last quarter. Successful Portfolios LLC raised its position in shares of Eli Lilly and Company by 2.5% during the second quarter. Successful Portfolios LLC now owns 1,301 shares of the company’s stock valued at $1,014,000 after buying an additional 32 shares during the last quarter. Finally, Grassi Investment Management raised its position in shares of Eli Lilly and Company by 0.3% during the second quarter. Grassi Investment Management now owns 79,927 shares of the company’s stock valued at $62,305,000 after buying an additional 200 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $840.46 on Friday. The firm has a market cap of $795.47 billion, a price-to-earnings ratio of 54.93, a PEG ratio of 1.14 and a beta of 0.47. The company has a 50 day moving average of $734.60 and a 200-day moving average of $766.47. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $937.00.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping the consensus estimate of $5.59 by $0.72. The company had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company’s revenue was up 37.6% on a year-over-year basis. During the same quarter last year, the business posted $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently commented on LLY. DZ Bank raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 14th. Morgan Stanley cut their price objective on shares of Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating for the company in a research report on Friday. Guggenheim dropped their price target on shares of Eli Lilly and Company from $942.00 to $875.00 and set a “buy” rating for the company in a research report on Wednesday, August 13th. Weiss Ratings reissued a “hold (c+)” rating on shares of Eli Lilly and Company in a research report on Saturday, September 27th. Finally, Leerink Partnrs lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have given a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $933.39.

Insider Activity at Eli Lilly and Company

In other news, CEO David A. Ricks acquired 1,632 shares of the company’s stock in a transaction dated Tuesday, August 12th. The stock was bought at an average price of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the acquisition, the chief executive officer owned 546,601 shares in the company, valued at approximately $352,431,926.77. This represents a 0.30% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Daniel Skovronsky acquired 1,000 shares of the company’s stock in a transaction dated Tuesday, August 12th. The shares were purchased at an average cost of $634.40 per share, with a total value of $634,400.00. Following the acquisition, the executive vice president owned 137,660 shares of the company’s stock, valued at approximately $87,331,504. This represents a 0.73% increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders have acquired 4,514 shares of company stock valued at $2,894,841. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.